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Abstract
A possible explanation for the relatively poor survival from breast cancer among blacks is the 
much higher rate of the adverse Triple-Negative sub-type. In a study of 1372 patients, blacks had 
twice the risk of death compared to whites among those with advanced cancer whether or not 
tumors were Triple-Negative. More research is still warranted to determine why blacks with 
advanced, but not local, breast cancer have a consistently higher rate of death.
Introduction—Emerging research suggests a substantially greater prevalence of the adverse 
triple-negative (TN) subtype (human epidermal growth factor receptor [HER]2−, estrogen receptor 
[ER]−, and progesterone receptor [PR])−) among black patients with breast cancer. No reports 
however have been generated from a statewide cancer registry.
Patients and Methods—The study consisted of all black patients (N = 643) and a random 
sample of white patients (n = 719) diagnosed with primary invasive breast cancer (2000–2003) 
listed in the National Cancer Institute–Surveillance Epidemiology and End Results (NCI-SEER) 
Connecticut Tumor Registry (CTR). HER2 status was obtained from pathology reports submitted 
to the registry. Remaining data were obtained from the registry database.
Results—TN tumors were more prevalent in black compared with white patients (30.8% vs. 
11.2%, respectively; P < .001.) There was a 2-fold greater frequency of ER− and PR− phenotypes 
among black patients, but HER2 status did not differ by race. Patients with lobular cancer were 
less likely to have TN breast cancer compared with patients with ductal tumors (odds ratio [OR] = 
0.23; 95% confidence interval [CI], 0.10–0.58). Among patients with regional disease, black 
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patients exhibited increased risk of death (relative risk [RR] = 2.71; 95% CI, 1.48–4.97) 
independent of TN status. No survival disparity was found among patients with local disease.
Discussion—These registry-based data corroborate reports that TN breast cancer varies 
substantially by race and histologic subtype. A survival disparity among patients with advanced 
disease, but not local disease, casts some doubt on TN status as an explanation for differences.
Conclusion—More research is warranted to understand why black patients with advanced breast 
cancer may be at increased risk for death whether or not their tumors express the TN phenotype.
Keywords
Biologic markers; Breast neoplasms; Health status disparities; HER2; Race/ethnicity; Triple 
negative breast cancer
Introduction
Despite consistently lower incidence rates for breast cancer, black patients have 
substantially higher mortality rates compared with whites.1–4 Disparate outcomes are likely 
due to an array of socioeconomic, behavioral, and clinic factors.1,5–7 Emerging evidence 
from hierarchical genome-wide classification studies also suggest that differential 
expression profiles may explain, in part, the mortality disparity. Four recently identified 
expression clusters, referred to as intrinsic subtypes, are thought to represent biologically 
distinct disease entities.8,9 Of these, the basal-like subtype tends to confer a significantly 
worse prognosis10,11 and has been found in an approximately 3-fold greater proportion 
among black patients compared with white patients.12 This subtype is characterized by low 
expression of the estrogen receptor (ER), progesterone receptor (PR), and human epidermal 
growth factor receptor 2 (HER2); high expression of proliferative genes, such as MK167, 
certain basal cytokeratins (eg, CK5, CK6, CK17), and EGFR1; frequent mutations in p53 
and other genes; and dysfunction of the BRCA1 gene.11,13 The other gene clusters are 
HER2-enriched, characterized by high expression of HER2 yet little or no expression of 
hormone receptors; luminal A, characterized mostly by expression of ER and associated 
genes; and luminal B, which is also mostly ER-expressing but is distinguished from luminal 
A by a relatively high-proliferation gene signature (eg, Ki-67) and a subset positive for 
HER2 expression.8,9,14,15
Because genomic expression profiling is not yet standard in the clinic setting, an 
immunohistochemical (IHC) designation known as triple-negative (TN) breast cancer (ER−, 
PR−, and HER2−) has emerged as a proxy categorization for the basal-like subtype.10,13 
Although TN breast cancer does not share many of the molecular features of the basal-like 
subtype, a number of studies have reported comparable associations with worse survival.10 
Results from a nested case study of 476 patients from a population-based cohort derived 
from the Atlanta metropolitan area reported that TN breast cancers were far more prevalent 
among younger women, particularly younger black women.16 Hospital-based case series 
from the Boston area17 and Marshfield Clinic18 in Wisconsin also reported an almost 
tripling of TN among black patients compared with white patients.
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To investigate the distributions and outcomes of TN breast cancer by race in a population-
based study, we used data from the Connecticut Tumor Registry (CTR), a statewide registry 
in the Surveillance, Epidemiology, and End Results (SEER) program of the National Cancer 
Institute (NCI). We performed a multiyear record review of 1362 patients with breast 
cancer, including all newly diagnosed breast cancers among black women and a comparably 
sized random sample of white women diagnosed during 2000–2003. To our knowledge, 
there have been no estimates of the prevalence and prognostic importance of the TN subtype 
derived from a statewide surveillance source.
Patients and Methods
Population
Data were obtained from the CTR, a participant site in the NCI-SEER program, on patients 
diagnosed with primary invasive female breast cancers (ICD-O-3 codes C500-C509) 
between January 1, 2000 and December 31, 2003. Of the full population of black patients 
with breast cancer during the study period, 96.5% (643/666) were included in analyses. 
Reasons for exclusions (n = 23) were duplicate records of the same case or discrepant 
information about racial status. A comparably sized random sample of white women (n 
=755) was selected from among 10,473 eligible cases in the CTR database. Matching on 
demographic variables was not performed in order to determine the actual prevalence of the 
variables under study. Of the 755 white women, 36 were excluded for reasons similar to 
those noted earlier, with a resultant total of 719 (95.2%) records reviewed. Access to patient 
information was approved by the Institutional Review Boards of the University of 
Connecticut Health Center and the State of Connecticut Department of Public Health.
Surveillance Epidemiology and End Results Database
Information obtained from the CTR database included the following: ER, PR, age at 
diagnosis, SEER summary stage at diagnosis (local, regional, and distant),15 ICD-O-3 
histologic subtypes,19 tumor grade (I, II, III/IV), number of positive axillary lymph nodes, 
and tumor size (cm). We combined all regional SEER summary substages into a single 
category. Histologic codes from World Health Organization ICD-O 3rd edition were used to 
create 5 subtypes: purely ductal (ICD-O codes 8500-8509, 8201); purely lobular (ICD-O 
code 8520); mixed ductal and lobular (ICD-O codes 8522-8524); medullary (ICD-O codes 
8510-8513) and other (eg, Paget disease, ICD-O code 8541; phyllodes, ICD-O code 9020), 
and un-classified (ICD-O codes 8000; 8010-8141; 8211, 8230, 8401, 8480, 8490; 
8530-8980). Ductal and lobular were separated based on evidence that HER2 is typically not 
expressed in lobular breast cancer.20,21 Procedures at the CTR for obtaining vital status and 
ICD cause of death have been reported in detail.22 Briefly, routine follow-up is obtained 
directly from reporting hospitals and through record linkages with state vital statistics, state 
motor vehicle records, centers for Medicare and Medicaid services, and the Social Security 
Administration. Cause of death is routinely obtained from computerized state death record 
files or the National Death Index Plus database. Vital status was selected as the clinical 
endpoint because recurrence or metastasis detected subsequent to the initial diagnosis is not 
routinely collected by SEER registries.
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HER2 Status
Summary pathology reports submitted to the CTR were reviewed to ascertain HER2 test 
result and summary descriptors (ie, positive or negative). Summary descriptors in the 
absence of a specific test value were accepted as HER2 status. If specific IHC test values 
were not accompanied by a summary descriptor, we classified positivity status in accordance 
with the prevailing scoring system during the study period (2000–2003) in which scores of 
2+ or 3+ indicated HER2 overexpression, and 0 or 1+were considered HER2−.23 Protocol to 
conduct confirmatory fluorescence in situ hybridization (FISH) testing for 2+IHC scores 
became standardized soon after the timeframe of our study.24 Of the 166 patients listed as 
having HER2+ tumors, 19 (11.4%) were considered unconfirmed 2+scores. Of the 37 cases 
listed descriptively (only) as borderline in the pathology report, 15 were subsequently tested 
by FISH, and of these, 2 were reported to be amplified. The remaining 13/15 were listed as 
HER2− in our analyses, as were the 22/37 borderline cases not subsequently tested by FISH. 
FISH results of ≥2 were classified as positive consistent with a recent survey of laboratory 
practices conducted by the College of American Pathologists.25 Records indicating findings 
for both FISH and IHC tests (n = 42) were classified according to FISH results. Reports in 
which the test result conflicted with the overall pathology report decision (eg, 3+ but 
deemed negative) were excluded from analyses (n = 22). As described in our earlier report, 
of patients whose pathology reports indicated that a HER2 test had been ordered, test results 
were available for 96% of black and 98% of white patients.26 The vast majority of the 
assays were IHC analyses, and less than 10% were IHC analyses followed by FISH or FISH 
alone.
Triple Subtypes
We used surrogate groupings based on IHC values for HER2, ER, and PR (Table 1) in 
accordance with groupings in recent studies.14,17,18,27 The summary pathology reports did 
not contain information on cytokeratins, HER1+, and other molecular components of the 
genomic-based intrinsic subtypes.
Statistical Analyses
Descriptive analyses comparing clinicopathologic characteristics between black and white 
patients were evaluated using a χ2 test for the categorical variables: triple subtypes (Table 
1), tumor grade (I/II, III/IV), histologic type, condensed SEER summary stage (local, 
regional, distant), HER2 status, ER status, PR status, tumor size category (< 2 cm, 2 cm to < 
5 cm, > 5 cm), axillary lymph node status (positive, negative), and vital status (alive, dead 
from any cause); t tests were used for independent samples to assess mean differences 
between black and white patients in regard to the following continuous variables: follow-up 
time among patients still alive at the end of the study period, age, tumor size, and number of 
positive axillary lymph nodes.
Logistic regression was performed to calculate odds ratios (ORs) and corresponding 95% 
confidence intervals (CIs) for binary outcomes of TN vs. non-TN breast cancers for black 
compared with white patients with breast cancer. Two multivariate models were constructed 
using established prognostic factors in breast cancer. Model 1 included patient age at 
diagnosis, tumor size (cm), tumor grade, and number of positive lymph nodes. Model 2 
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added histologic subtypes. Multivariate models were forced (ie, established prognostic 
factors) and Hosmer-Lemeshow goodness of fit (GOF) tests were nonsignificant (model 1: 
GOF χ2 = 3.89; P = .87; model 2: GOF χ2 =9.63; P =.29), indicating that model predictions 
did not differ significantly from observations.
Differences in survival time between the dichotomous study groups (TN, non-TN) were 
estimated using Cox multivariate proportional hazards analysis and illustrated with Kaplan-
Meier curves. We stratified analyses a priori by SEER summary stage of disease (local, 
regional, distant) because of the mixed evidence of prognostic value of HER2 status in node-
negative patients.28 Two forced models were constructed using the same variables included 
in the logistic regression. Survival time among patients who died was defined as months 
from date of diagnosis to date of death. Patients alive at the end of the study were right-
censored, with a survival time endpoint of date of last follow-up. Outcome event was any 
cause of death as listed in the CTR database. Survival analyses excluded patients with 
distant disease because of the very poor 5-year survival rate4 and those who survived less 
than 1 month after diagnosis to exclude possible surgical failures (n =1). All statistical 
analyses were carried out using PASW Statistics version 17.0 (formerly SPSS Statistics; 
SPSS, Chicago, IL) and were assessed with 2-sided P values.
Results
As shown in Table 2, when compared with whites, black patients with breast cancer were 
diagnosed at a younger age (mean of 57.6 vs. 62.5 years, respectively; P <.001), were more 
likely to be <50 years (33.1% vs. 21.1%, respectively; P < .001), and presented with higher 
grade (P <.001) and larger tumors (mean of 2.32 cm vs. 2.00 cm; P < .001). White patients 
had nearly twice the prevalence of lobular tumors (9.3% vs. 5.3%; omnibus P = .001) and a 
markedly lower prevalence of medullary tumors (0.4% vs. 3.3%; omnibus P = .001) 
compared with black patients. Compared with whites, black patients presented with 
somewhat larger tumors on average (2.00 vs. 2.32 cm, respectively; P < .001).
Distribution of HER2/ER/PR Subtypes Varied by Race
Compared with white patients, black patients with breast cancer had nearly 3 times the 
prevalence of TN breast cancer, and almost double the rate of the ER−/PR−/HER2+ subtype 
(30.8% vs. 11.2%, 9.2% vs. 4.8%, respectively; omnibus P < .001) (Table 3). This 
distribution did not change appreciably when counting 2+ IHC values as HER2− (31.7% vs. 
11.0%, 7.9% vs. 4.7%, respectively; omnibus P < .001; data not shown). Tumors from black 
patients were far more likely than those from whites to test negative for estrogen (39.7% vs. 
17.6%, respectively; P < .001) and progesterone (47.3% vs. 29.2%, respectively; P < .001) 
receptors, yet exhibited a comparable rate of HER2 positivity to that of whites (20.5% vs. 
17.1%, respectively; P =0.19). HER2 positivity rates for black and white patients did not 
change appreciably when counting 2+ IHC scores as negative for overexpression (16.0% vs. 
16.1%, respectively; P = 0.94; data not shown). TN frequency was somewhat lower in 
patients with local disease (18.3%) compared with those with regional and distant stages at 
presentation (25.1%, 27.8%, respectively; P = .049, data not shown).
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As seen in Table 4, black women were almost 3 times more likely than white women to be 
diagnosed with TN breast cancer (multivariate OR = 2.93; 95% CI, 1.88–4.57) when 
controlling for age at diagnosis, tumor size, tumor grade, and number of positive nodes in 
model 1, which persisted when histologic subtype was added as a covariate (multivariate OR 
= 2.95; 95% CI, 1.87–4.66) in model 2. Patients with purely lobular cancers however were 
significantly less likely to present with TN breast cancer compared with the study referent 
group of those with purely ductal cancers (multivariate OR = 0.25; 95% CI, 0.07–0.89). 
Likewise patients with mixed lobular and ductal disease were significantly less likely to 
have TN tumors (multivariate OR = 0.23; 95% CI, 0.10–0.58). Conversely patients with 
medullary tumors were 3.37 times more likely (95% CI, 0.94–12.10) to present with TN 
breast cancer, but this finding did not reach statistical significance (P < .06).
Given the variation in TN status by race and histologic subtype (Table 4), we examined if 
differences held for each of the underlying 3 biomarkers (HER2, ER, and PR). Descriptive 
analyses in Table 5 show that the frequency of HER2 positivity did not vary by race in 
tumors with ductal or lobular histologic features, although lobular-based tumors tended to 
display lower HER2 expression. ER and PR phenotypes however varied substantially by 
both race and histologic features. For those with purely ductal tumors, eg, twice as many 
black patients were diagnosed with the more adverse ER− phenotype compared with whites 
(44.7% vs. 20.3%, respectively; P < .001). For lobular-based breast cancer, the difference in 
ER negativity was nearly 3-fold for blacks compared with whites (15.0% vs. 5.3%, 
respectively; P = .01). Similar patterns were observed for PR status, but the difference 
between black and white patients was not statistically significant. Overall, a greater 
proportion of ductal tumors, compared with those of pure or composite lobular histologic 
characteristics, expressed the TN phenotype (23.0% vs. 6.4%, respectively; P < .001; data 
not shown) or were HER2+ (21.2% vs. 13.8%, respectively; P <.05; data not shown). In 
contrast, tumors of purely ductal histologic features were more likely to be ER− compared 
with lobular-based tumors (68.2% vs. 90.5%, respectively; P < .001.) More than 90.0% of 
tumors with a lobular component did not express the TN phenotype, which did not differ by 
race (P = 0.95). There were too few patients (n =156) with other histologic subtypes (eg, 
medullary) to have reliable counts in the stratified race, subtype, and histologic type cross-
tabulations.
Black breast cancer patients with local disease had a 40% increased risk of death (Table 6A) 
compared with white patients in the age-adjusted analysis (RR, 1.41; 95% CI, 1.03–1.93), 
but risk estimates were reduced to null in the multivariate models. When examining regional 
disease (Table 6B) however black patients with breast cancer exhibited a more than doubled 
risk of death compared with whites in age-adjusted analyses, which was maintained in the 2 
multivariate models. Univariate Kaplan-Meier curves (Figure 1) illustrate survival patterns 
according to race and stage. Among patients with TN tumors, there were no differences in 
survival between blacks and whites for patients who presented with local stage disease 
(Figure 1A). However among patients with regional stage diagnoses (Figure 1B), blacks had 
worse survival than whites (Mantel-Cox log-rank test, P =.005). A similar variation in 
survival was observed for patients with non-TN breast cancer (Figure 1C, D). Black patients 
with TN tumors and regional disease had the shortest survival time.
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To assess possible selection bias because of the large number of patients excluded resulting 
from missing data on TN status (n = 467), which was mostly because of unknown HER2 
status, we compared several characteristics of included vs. excluded patients (data not 
shown). Included patients were younger on average (mean of 59.0 years vs. 61.8 years, 
respectively; P =.001) and were somewhat more likely to be black (49.4% of included vs. 
43.7% of excluded; P =.05). The percent of patients still living at the end of the follow-up 
period did not vary between the 2 sets of patients (P = .71) nor did the distribution of 
histologic subtypes (P = .46). To further assess possible selection bias related to 
overrepresentation of younger patients in our study, we stratified TN prevalence to explore 
if this phenotype might vary by menopausal status using the surrogate measure of age (data 
not shown). We found that for patients ≤50 years, 35.7% of black patients presented with 
TN tumors compared with only 11.3% of white patients (P = .001). Similarly for those > 50 
years of age, the proportion of TN tumors among black patients was reduced 2-fold (26.4% 
vs. 11.1%, respectively; P < .001). Notably TN prevalence did not vary by age among white 
patients.
Discussion
In this analysis from a statewide cancer registry, we found a 2- to 3-fold difference in the 
prevalence of TN breast cancer among blacks compared with whites, in keeping with recent 
hospital-based and population-based clinical studies.16–18,29,30 We found that the rate of TN 
tumors remained at about 11% for white patients both older and younger than 50 years, but 
varied by age among black patients (35% vs. 24%, respectively.) Our findings also are 
similar to previous reports that tumors from black patients with breast cancer tend to have 
significantly reduced ER or PR expression,31,32 whereas HER2 status does not appear to 
vary by race.7,33,34 Our findings suggest that divergent histologic distribution by race may 
underlie the disparity in TN status. Although the medullary subtype is relatively rare, we 
found that blacks had an almost 9-fold greater rate than that of white patients (3.3% vs. 
0.40%), which is consistent with several earlier reports.32,35,36 Further, as in our analysis it 
has been reported that medullary tumors have a relatively higher rate of the TN phenotype.10 
We speculate that the higher prevalence of TN tumors among black patients might explain 
in part survival disparity because several studies have reported that this subtype is relatively 
more aggressive because of its high nuclear grade.37 Others however have reported that 
medullary cancer confers a favorable prognosis despite sharing features with breast cancer 
subtypes that have a poor prognosis.38 We did not have sufficient numbers of patients with 
medullary cancer to perform a thorough prognostic analysis, however. Future investigations 
of disparities, particularly of TN breast cancer, would benefit from oversampling of 
medullary and other rare types so that race and age patterns can be explored more fully.
Recent investigations have shed some light on the possible origins of TN tumors. A recent 
study reported that patients with TN tumors were more likely to be obese or overweight 
compared with patients with tumors exhibiting the ER+/PR+/HER2+ phenotype.27 Authors 
also found that ER− and PR− tumors were associated with younger age at birth of first child. 
However Stead et al found TN status to be independent of age and weight.17 Kwan et al 
observed that the association between obesity/overweight and TN breast cancer was seen 
among premenopausal but not postmenopausal women.29 In the Carolina Breast Cancer 
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Study, increased parity raised the risk of basal-like breast cancer,37 which may be attenuated 
by relatively longer duration of breastfeeding as observed in 2 recent studies.29,38 A recent 
analysis by Huo et al in indigenous Nigeria and Senegal suggests that both behavioral and 
genetic background influence breast cancer subtype prevalence.39 Investigators reported a 
27% prevalence of the basal-like subtype and a 17% prevalence of HER2+ breast cancers, 
which are consistent with our study and other analyses cited earlier in the African diaspora 
in the United States. Variation in subtype prevalence within indigenous populations implies 
etiologic heterogeneity, whereas similarity in prevalence across different geographic 
locations suggests a degree of genetic predisposition. Troester and Swift-Scanlan suggest 
that to better clarify risk factors for TN breast cancer, attention should be given to the age 
and racial compositions of study populations,40 to which we would like to add that 
histologic subtypes also may be informative.
Our multivariate findings of an increased risk of death among patients with TN tumors is 
consistent with previous reports,16 including survival studies based on the basal-like 
classification.12 Conversely our study, along with that of Carey et al in the Carolina Breast 
Study12 and of Lund et al’s study in the Atlanta metropolitan area,16 casts some doubt that 
the substantial differential TN frequency explains survival disparity. We observed that 
disparities in survival were present only among patients with regional disease irrespective of 
TN status, which suggests that other influences may be at play within an otherwise 
homogeneous high-risk group. Lund et al found, eg, that disparities in treatment underlay 
survival differences in their large study.41 It also is possible that because IHC-based TN 
status is an imperfect surrogate for the microarray-derived basal-like subtype, other 
molecular factors (eg, BRCA1, basal cytokeratins, p53) might better distinguish black and 
white patients with advanced tumors. Although there is sizeable discordance between TN 
and basal-like subtype,13 evaluating the prognostic utility of TN continues to be of 
importance because microarray assays are not yet standard in routine practice resulting from 
high costs and time intensity. Further there is no targeted therapy for TN tumors by 
definition of their negativity, which otherwise would allow use of, eg, trastuzumab for 
HER2+ disease or chemoantagonists for hormone receptor–expressing tumors.10 Hence 
clarifying risk estimates for TN subgroups (eg, regional disease, lobular histologic type) 
may be of value for patient surveillance planning.
A secondary aim of our investigation was to evaluate the research utility of summary 
hospital pathology reports to obtain HER2 status for studies of NCI-SEER registry 
databases. NCI included HER2 as a reportable item in the SEER program starting with 
diagnosis year 2010.42 Until a sufficient number of years have transpired to conduct 
outcome studies however, researchers still may wish to obtain HER2 data from before 2010. 
Our previous analysis of patterns of HER2 testing in the current set of patients26 indicated 
that approximately two thirds of them were tested for the biomarker. Lack of HER2 status in 
the report was the primary cause of missing TN status in our current study, but this gap is 
expected to be alleviated in the coming years now that HER2 status is a SEER reportable 
item. Despite missing information, our finding of a lack of significant difference in HER2 
positivity between black and white patients is corroborated by several earlier 
reports.1,7,12,33,34,43 HER2 positivity in our study (IHC 2+ scores deemed either positive or 
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negative) falls within the range of recent reports estimating prevalence to be 12% to 25% of 
sampled tumors,12,43–46 which is a narrowing from initial estimates that ranged up to 40%. 
It is likely that early studies overestimated prevalence because these investigations tended to 
be composed of high-risk cohorts or proportionally more patients with regional or metastatic 
disease.23 Designation of 2+ scores as HER2+ might have introduced some error into our 
study because we did not have information on FISH confirmation for most cases. We 
speculate however that only a fraction of those cases subsequently would have been changed 
to TN because the great majority of tumors were ER+ and/or PR+.
Information in pathology reports at a central registry may be a relatively bias-free source of 
HER2 status data because of nearly complete registration of all patients in the population 
and the fact that HER2 status is based on surgical tissue used for diagnostic purposes and is 
not dependent on tissue availability in residual archives, as is the case in conventional 
investigations. Lack of tissue for research can be a source of substantial selection bias.21 
Studies using research archives or residual hospital biobanks have reported that tumors from 
patients for whom tissue was available tended to be significantly larger than those for whom 
tissue was no longer available.12,21,28 Overrepresentation of larger tumors may result in a 
bias toward the null in survival analyses; a single tumor marker or even a comprehensive 
molecular profile might not stand out as an independent factor in the context of advanced 
anatomic burden and concomitant genetic changes as tumors progress through the metastatic 
cascade.28
Conclusion
Our findings benefit from 4 years of data derived from a well-established, population-based, 
statewide cancer registry recognized for high quality and complete data.47 Still our results 
should be interpreted with some caution. The large proportion of missing data on HER2 
status raises the prospect of bias due to an unmeasured confounder. Our prevalence and 
survival results, however, are consistent with earlier evidence, which offers the first 
supportive evidence of the general accuracy of HER2 data in a SEER registry. Lack of 
information on treatment is another limitation in our study. Given evidence of reported 
disparities in both receipt of treatment and prognostic factors in breast cancer,41 future TN 
studies should examine patterns of care, particularly for agents with known resistance or 
enhanced sensitivity to HER2+ tumors. Additionally, insurance coverage, socioeconomic 
status, patient decision making, and presence of comorbidities (eg, diabetes, heart disease) 
also may influence treatment use or effectiveness. Understanding treatment-related 
dynamics may illuminate why, in the community setting, black patients with advanced 
breast cancer disease appear to be at increased risk for death whether or not their tumors 
expressed the TN phenotype. Emerging research has focused on the roughly 3-fold greater 
prevalence of the adverse TN phenotype in tumors of black patients as a possible 
explanation for survival disparity. However our stratified survival analyses cast some doubt 
on that hypothesis. Our findings may be applied to the future practice of cancer medicine by 
contributing to improved prognostic assessment of patients with breast cancer, particularly 
for black patients who have a substantially higher mortality rate despite a lower incidence of 
breast cancer.
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Clinical Practice Points
Despite consistently lower incidence rates for breast cancer, black patients tend to have 
substantially higher mortality rates compared to whites. Emerging research suggests that 
the greater prevalence of the adverse Triple-Negative subtype among black breast cancer 
patients might contribute to the disparity in outcome.
Among patients with regional disease, black patients exhibited reduced survival 
compared to whites while controlling for Triple-Negative status, age, tumor size, number 
of positive axillary lymph nodes, tumor grade, and histological subtype. In contrast, we 
found no evidence of disparity among patients with local stage disease.
Until reasons for survival disparity are better understood, black patients with regional 
disease may need heightened monitoring for recurrence even if their tumors do not 
exhibit the relatively aggressive TN phenotype.
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Figure 1. 
Kaplan-Meier Survival Curves Depicting Overall Survival from Breast Cancer in Relation to 
Triple-Negative Tumor Status and SEER Summary Stage, NCI-SEER Connecticut Tumor 
Registry, 2000–2003
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Table 1
Definition of IHC-based Breast Cancer Subtypes
IHC Values Variable Label Surrogate for Intrinsic Subtype
ER− PR− HER2− ER− PR− HER−- Basal-like
ER− PR− HER2+ ER− PR− HER2+ HER2-enriched
ER+PR+HER2− ER/PR+ HER2− Luminal A
ER-PR+HER2−
ER+PR− HER2−
ER+PR+HER2+ ER/PR+ HER2+ Luminal B
ER− PR+HER2+
ER+PR− HER2+
Abbreviations: ER = estrogen receptor; HER = human epidermal growth factor receptor; PR = progesterone receptor.
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Table 2
Clinicopathologic Characteristics of 1362 Breast Cancer Patients According to Race, NCI-SEER Connecticut 
Tumor Registry, 2000–2003
White (n =719) Black (n =643) P Valuea,b
Alive n (%) 543 (75.5%) 457 (71.1%) .06
Median Follow-up Time Among Alive 73.2 months 68.1 months
.03c
Age at Diagnosis (Years)
 Mean (SD) 62.5 (14.8) 57.6 (14.1) < .001
 < 50 152 (21.1%) 213 (33.1%) < .001
 50+ 567 (78.9%) 430 (66.9%)
SEER Summary Stage
 Local 452 (64.5%) 379 (60.7%) .29
 Regional 213 (30.4%) 215 (34.5%)
 Distant 36 (5.1%) 30 (4.8%)
 Unstaged/missing 18 19
Histologic Subtype
 Ductal 490 (69.4%) 434 (67.6%) .001
 Lobular 66 (9.3%) 34 (5.3%)
 Mixed ductal and lobular 85(12.0%) 84 (13.1%)
 Medullary 3 (0.4%) 21 (3.3%)
 Other or unclassified 62 (8.8%) 69 (10.7%)
 Unknown 13 1
Tumor Grade
 I 94 (15.1%) 57 (9.9%) .001
 II 262 (42.0%) 213 (37.1%)
 III/IV 268 (42.9%) 304 (53.0%)
 Unknown 69 95
Axillary Lymph Nodes
 Mean no. positive (SD) 1.20 (2.9) 1.36 (3.2) .39
 Negative 365 (65.2%) 312 (60.3%) .10
 Positive 195 (34.8%) 205 (39.7%)
 Not examined/unknown 159 126
Tumor Size
 Mean mm (SD) 2.00 (1.6) 2.32 (1.8) .001
 < 2 392 (60.1%) 289 (50.3%) .001
 2 to < 5 216 (33.1%) 225 (39.1%)
 > 5 44 (6.7%) 61 (10.6%)
 Unknown 64 64
 Diffuse 3 4
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Abbreviation: SEER = Surveillance Epidemiology and End Results.
aCategorical variables evaluated with Pearson χ2 test of proportions.
bContinuous variables evaluated with t test for independent samples except where noted.
c
Evaluated using the Mann-Whitney nonparametric test.
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Table 3
HER2, ER, and PR status of Tumors from 1362 Breast Cancer Patients According to Race, NCI-SEER 
Connecticut Tumor Registry, 2000–2003
Tumor Status White (n =719) Black (n =643) Pearson χ2 P Value
Triple Subtype
 ER− PR− HER2− 47 (11.2%) 128 (30.8%) < .001
 ER− PR− HER2+ 20 (4.8%) 38 (9.2%)
 ER/PR+ HER2− 301 (71.5%) 205 (49.4%)
 ER/PR+ HER2+ 53 (12.6%) 44 (10.6%)
 Missing 298 228
HER2
 Positive 76 (17.1%) 90 (20.5%) .19
 Negative 369 (82.9%) 350 (79.5%)
 Missing 274 203
ER
 Positive 483 (82.4%) 318 (60.3%) < .001
 Negative 103 (17.6%) 209 (39.7%)
 Missing 133 116
PR
 Positive 407 (70.8%) 275 (53.7%) < .001
 Negative 168 (29.2%) 247 (47.3%)
 Missing 144 121
Abbreviations: ER = estrogen receptor; HER = human epidermal growth factor receptor; PR = progesterone receptor.
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Table 4
Age-Adjusted and Multivariate Odds Ratio (OR) for Invasive Triple-negativea Breast Cancer, NCI-SEER 
Connecticut Tumor Registry, 2000–2003
Variable Age-Adjusted OR (95% CI) (n =836)
Multivariate Model 1 b OR 
(95% CI) (n =823)
Multivariate Model b OR (95% 
CI) (n =789)
Race
 White 1.00 1.00 1.00
 Black 3.37 (2.33–4.89) 2.93 (1.88–4.57) 2.95 (1.87–4.66)
Tumor Size (cm) – 1.17 (1.02–1.33) 1.16 (1.01–1.33)
Axillary Lymph Nodes (no. positive) – 1.00 (0.95–1.06) 1.02 (0.95–1.08)
Tumor Grade
 I/II – 1.00 1.00
 III/IV 6.74 (4.04–11.27) 6.83 (3.99–11.72)
Histologic Subtype
 Ductal – 1.0
 Lobular – 0.25 (0.07–0.89)
 Mixed ductal and lobular 0.23 (0.10–0.58)
 Medullary 3.37 (0.94–12.10)c
 Other or unclassified 1.97 (0.78–4.97)
aCompared with all other triple subtypes combined.
bAll variables (and age) simultaneously assessed in models.
c
P = .06.
Clin Breast Cancer. Author manuscript; available in PMC 2015 June 08.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Swede et al. Page 20
Ta
bl
e 
5
H
ER
2,
 E
R,
 a
nd
 P
R 
St
at
us
 in
 In
va
siv
e 
Br
ea
st 
Ca
nc
er
 b
y 
M
ajo
r H
ist
olo
gic
 Su
bty
pe
s, N
CI
-SE
ER
 C
on
ne
cti
cu
t T
um
or 
Re
gis
try
, 2
00
0–
20
03
V
ar
ia
bl
e
D
uc
ta
l
Pu
re
ly
 L
ob
ul
ar
 o
r 
M
ix
ed
 L
ob
ul
ar
-D
uc
ta
l
W
hi
te
 (n
 =4
90
)
Bl
ac
k 
(n
 =4
34
)
Pe
ar
so
n 
χ2
 
P 
V
al
ue
W
hi
te
 (n
 =1
51
)
Bl
ac
k 
(n
 =1
18
)
Pe
ar
so
n 
χ2
 
P 
V
al
ue
Tr
ip
le
 S
ub
ty
pe
 
Tr
ip
le
-n
eg
at
iv
e
34
 (1
1.7
%)
97
 (3
4.8
%)
6 
(6.
5%
)
5 
(6.
3%
)
 
N
on
-tr
ip
le
-n
eg
at
iv
e
25
6 
(88
.3%
)
18
2 
(65
.2%
)
<
 .0
01
87
 (9
5.3
%)
75
 (9
3.8
%)
.
95
 
M
iss
in
g
20
0
15
5
58
38
H
ER
2
 
Po
sit
iv
e
59
 (1
9.0
%)
70
 (2
3.5
%)
12
 (1
2.4
.%
)
13
 (1
5.5
%)
 
N
eg
at
iv
e
25
1 
(81
.0%
)
22
8 
(76
.5%
)
.
19
85
 (8
7.6
%)
71
 (8
4.5
%)
.
54
 
M
iss
in
g
18
0
13
6
54
34
ER  
Po
sit
iv
e
32
1 
(79
.7%
)
19
8 
(55
.3%
)
12
4 
(94
.7%
)
85
 (8
5.0
%)
 
N
eg
at
iv
e
82
 (2
0.3
%)
16
0 
(44
.7%
)
<
 .0
01
7 
(5.
3%
)
15
 (1
5.0
%)
.
01
 
M
iss
in
g
87
76
20
18
PR  
Po
sit
iv
e
27
0 
(68
.4%
)
17
2 
(48
.9%
)
10
5 
(81
.4%
)
75
 (7
4.3
9%
)
 
N
eg
at
iv
e
12
5 
(31
.6%
)
18
0 
(51
.1%
)
<
 .0
01
24
 (1
8.6
%)
26
 (2
5.7
%)
.
19
 
M
iss
in
g
95
82
22
17
A
bb
re
vi
at
io
ns
: E
R 
= 
es
tro
ge
n 
re
ce
pt
or
; H
ER
 =
 h
um
an
 e
nd
ot
he
lia
l r
ec
ep
to
r; 
PR
 =
 p
ro
ge
ste
ro
ne
 re
ce
pt
or
.
Clin Breast Cancer. Author manuscript; available in PMC 2015 June 08.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Swede et al. Page 21
Table 6
Age-Adjusted and Multivariate Relative Risk (RR) of All-Cause Death in Relation to Triple-Negative Breast 
Cancer and Race Derived from Cox Proportional Hazards Survival Analyses,a NCI-SEER Connecticut Tumor 
Registry, 2000–2003
A: LOCAL STAGE AT DIAGNOSIS
Age-Adjusted b RR (95% CI) Multivariate Model 1c RR (95% CI) (n =420)
Multivariate Model 2c RR (95% CI) 
(n =420)
Race
 White 1.00 1.00 1.00
 Black 1.41 (1.03–1.93) 1.03 (0.60–1.77) 1.05 (0.60–1.81)
Triple Subtype
 Non–triple-negative 1.00 1.00 1.00
 Triple-negative 2.79 (1.769–4.34) 2.67 (1.43–4.97) 2.74 (1.47–5.15)
Tumor Size (cm) – 1.02 (1.01–1.04) 1.02 (1.01–1.04)
Tumor Grade
 I/II – 1.00 1.00
 III/IV 1.15 (0.65–2.05) 1.09 (0.61–1.94)
Histologic Subtype
 Ductal – 1.00
 Lobular – 1.49 (0.52–4.25)
 Mixed ductal and lobular 0.89 (0.38–2.12)
 Medullary 1.13 (0.27–4.76)
 Other or unclassified 0.56 (0.13–2.37)
B: REGIONAL STAGE AT DIAGNOSIS
Age-Adjusted b RR (95% 
CI)
Multivariate Model 1c RR 
(95% CI) (n =242)
Multivariate Model 2c RR (95% 
CI) (n =242)
Race
 White 1.00 1.00 1.00
 Black 2.19 (1.51–3.17) 2.79 (1.54–5.10) 2.71 (1.48–4.97)
Triple Subtype
 Non-triple-negative 1.00 1.00 1.00
 Triple-negative 3.03 (1.93–4.75) 2.15 (1.26–3.75) 2.13 (1.20–3.75)
Tumor Size (cm) – 1.01 (0.99–1.02) 1.01 (0.99–1.02)
Positive Axillary Nodes (number) – 1.05 (1.02–1.09) 1.06 (1.02–1.09)
Tumor Grade
 I/II – 1.00 1.00
 III/IV 2.27 (1.16–4.42) 2.43 (1.23–4.77)
Histologic Subtype
 Ductal – 1.00
 Lobular – 1.49 (0.52–4.25)
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B: REGIONAL STAGE AT DIAGNOSIS
Age-Adjusted b RR (95% 
CI)
Multivariate Model 1c RR 
(95% CI) (n =242)
Multivariate Model 2c RR (95% 
CI) (n =242)
 Mixed ductal and lobular 0.49 (0.17–1.39)
 Medullary 0.31 (0.04–4.76)
 Other or unclassified 1.63 (0.49–5.34)
Abbreviations: CI = confidence interval; RR = relative risk.
a
Excluded patents with distant disease at diagnosis or who survived less than 1 month.
bAge-adjusted RRs calculated separately for race (n = 672) and triple subtype (n = 438).
cAll variables in model simultaneously controlled.
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